These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16131816)

  • 1. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment.
    Aapro M
    Oncology; 2005; 69(2):97-109. PubMed ID: 16131816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
    Aapro M; Johnson J
    Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Aapro M
    Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
    Constenla M
    Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of 5-HT3 receptor antagonists: clinical overview and nursing implications.
    Bremerkamp M
    Clin J Oncol Nurs; 2000; 4(5):201-7. PubMed ID: 11111451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment options for chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    Support Care Cancer; 2004 Aug; 12(8):550-4. PubMed ID: 15232725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.